Dermata receives Australian patent for Spongilla acne treatment technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
January 20, 2026 8:05 AM ESTThis patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne
Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.
Over 3.3 million people are diagnosed with acne in Australia
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 20, 2026 /... More
